Report cover image

Global Gastrointestinal Stromal Tumor Drug Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 215 Pages
SKU # APRC20283775

Description

Summary

According to APO Research, The global Gastrointestinal Stromal Tumor Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Gastrointestinal Stromal Tumor Drug include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Gastrointestinal Stromal Tumor Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Gastrointestinal Stromal Tumor Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Gastrointestinal Stromal Tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastrointestinal Stromal Tumor Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastrointestinal Stromal Tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastrointestinal Stromal Tumor Drug sales, projected growth trends, production technology, application and end-user industry.

Gastrointestinal Stromal Tumor Drug Segment by Company

China Biopharmaceuticals
Zai Lab
CSPC Pharmaceuticals
Novartis
Mylan Pharms Inc.
Kelun Pharmaceuticals
CStone Pharmaceuticals
Hansoh Pharmaceuticals
Vannsh Life Sciences
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceuticals
MSN Laboratories
Glenmark Pharmaceuticals Ltd.
Drug International
Dr. Reddy's Laboratories
Deciphera Pharmaceuticals
Bulat Pharmaceutical
Beacon Pharmaceuticals
Bayer Pharmaceuticals
Apotex Inc.
Actavis Generics
Gastrointestinal Stromal Tumor Drug Segment by Type

Ripretinib
Regorafenib
Sunitinib
Imatinib
Others
Gastrointestinal Stromal Tumor Drug Segment by Application

Hospital
Clinic
Others
Gastrointestinal Stromal Tumor Drug Segment by Region

North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Gastrointestinal Stromal Tumor Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastrointestinal Stromal Tumor Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

215 Pages
1 Market Overview
1.1 Product Definition
1.2 Gastrointestinal Stromal Tumor Drug Market by Type
1.2.1 Global Gastrointestinal Stromal Tumor Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Ripretinib
1.2.3 Regorafenib
1.2.4 Sunitinib
1.2.5 Imatinib
1.2.6 Others
1.3 Gastrointestinal Stromal Tumor Drug Market by Application
1.3.1 Global Gastrointestinal Stromal Tumor Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Gastrointestinal Stromal Tumor Drug Market Dynamics
2.1 Gastrointestinal Stromal Tumor Drug Industry Trends
2.2 Gastrointestinal Stromal Tumor Drug Industry Drivers
2.3 Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges
2.4 Gastrointestinal Stromal Tumor Drug Industry Restraints
3 Global Market Growth Prospects
3.1 Global Gastrointestinal Stromal Tumor Drug Revenue Estimates and Forecasts (2020-2031)
3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region
3.2.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2020-2025)
3.2.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2026-2031)
3.2.4 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2020-2031)
3.3 Global Gastrointestinal Stromal Tumor Drug Sales Estimates and Forecasts 2020-2031
3.4 Global Gastrointestinal Stromal Tumor Drug Sales by Region
3.4.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2020-2025)
3.4.3 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2026-2031)
3.4.4 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Manufacturers
4.1.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Manufacturers (2020-2025)
4.1.2 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Gastrointestinal Stromal Tumor Drug Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Gastrointestinal Stromal Tumor Drug Sales by Manufacturers
4.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Manufacturers (2020-2025)
4.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Gastrointestinal Stromal Tumor Drug Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Gastrointestinal Stromal Tumor Drug Sales Price by Manufacturers (2020-2025)
4.4 Global Gastrointestinal Stromal Tumor Drug Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Gastrointestinal Stromal Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Gastrointestinal Stromal Tumor Drug Manufacturers, Product Type & Application
4.7 Global Gastrointestinal Stromal Tumor Drug Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Gastrointestinal Stromal Tumor Drug Market CR5 and HHI
4.8.2 2024 Gastrointestinal Stromal Tumor Drug Tier 1, Tier 2, and Tier 3
5 Gastrointestinal Stromal Tumor Drug Market by Type
5.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Type
5.1.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2020-2031)
5.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type
5.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2020-2031) & (K Units)
5.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2020-2031)
5.3 Global Gastrointestinal Stromal Tumor Drug Price by Type
6 Gastrointestinal Stromal Tumor Drug Market by Application
6.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Application
6.1.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2020-2031)
6.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application
6.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2020-2031) & (K Units)
6.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2020-2031)
6.3 Global Gastrointestinal Stromal Tumor Drug Price by Application
7 Company Profiles
7.1 China Biopharmaceuticals
7.1.1 China Biopharmaceuticals Comapny Information
7.1.2 China Biopharmaceuticals Business Overview
7.1.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.1.5 China Biopharmaceuticals Recent Developments
7.2 Zai Lab
7.2.1 Zai Lab Comapny Information
7.2.2 Zai Lab Business Overview
7.2.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
7.2.5 Zai Lab Recent Developments
7.3 CSPC Pharmaceuticals
7.3.1 CSPC Pharmaceuticals Comapny Information
7.3.2 CSPC Pharmaceuticals Business Overview
7.3.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.3.5 CSPC Pharmaceuticals Recent Developments
7.4 Novartis
7.4.1 Novartis Comapny Information
7.4.2 Novartis Business Overview
7.4.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
7.4.5 Novartis Recent Developments
7.5 Mylan Pharms Inc.
7.5.1 Mylan Pharms Inc. Comapny Information
7.5.2 Mylan Pharms Inc. Business Overview
7.5.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
7.5.5 Mylan Pharms Inc. Recent Developments
7.6 Kelun Pharmaceuticals
7.6.1 Kelun Pharmaceuticals Comapny Information
7.6.2 Kelun Pharmaceuticals Business Overview
7.6.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.6.5 Kelun Pharmaceuticals Recent Developments
7.7 CStone Pharmaceuticals
7.7.1 CStone Pharmaceuticals Comapny Information
7.7.2 CStone Pharmaceuticals Business Overview
7.7.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.7.5 CStone Pharmaceuticals Recent Developments
7.8 Hansoh Pharmaceuticals
7.8.1 Hansoh Pharmaceuticals Comapny Information
7.8.2 Hansoh Pharmaceuticals Business Overview
7.8.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.8.5 Hansoh Pharmaceuticals Recent Developments
7.9 Vannsh Life Sciences
7.9.1 Vannsh Life Sciences Comapny Information
7.9.2 Vannsh Life Sciences Business Overview
7.9.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
7.9.5 Vannsh Life Sciences Recent Developments
7.10 Teva Pharmaceutical Industries Ltd.
7.10.1 Teva Pharmaceutical Industries Ltd. Comapny Information
7.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.10.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
7.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
7.11 Sun Pharmaceuticals
7.11.1 Sun Pharmaceuticals Comapny Information
7.11.2 Sun Pharmaceuticals Business Overview
7.11.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.11.5 Sun Pharmaceuticals Recent Developments
7.12 MSN Laboratories
7.12.1 MSN Laboratories Comapny Information
7.12.2 MSN Laboratories Business Overview
7.12.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
7.12.5 MSN Laboratories Recent Developments
7.13 Glenmark Pharmaceuticals Ltd.
7.13.1 Glenmark Pharmaceuticals Ltd. Comapny Information
7.13.2 Glenmark Pharmaceuticals Ltd. Business Overview
7.13.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
7.13.5 Glenmark Pharmaceuticals Ltd. Recent Developments
7.14 Drug International
7.14.1 Drug International Comapny Information
7.14.2 Drug International Business Overview
7.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
7.14.5 Drug International Recent Developments
7.15 Dr. Reddy's Laboratories
7.15.1 Dr. Reddy's Laboratories Comapny Information
7.15.2 Dr. Reddy's Laboratories Business Overview
7.15.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
7.15.5 Dr. Reddy's Laboratories Recent Developments
7.16 Deciphera Pharmaceuticals
7.16.1 Deciphera Pharmaceuticals Comapny Information
7.16.2 Deciphera Pharmaceuticals Business Overview
7.16.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.16.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.16.5 Deciphera Pharmaceuticals Recent Developments
7.17 Bulat Pharmaceutical
7.17.1 Bulat Pharmaceutical Comapny Information
7.17.2 Bulat Pharmaceutical Business Overview
7.17.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.17.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
7.17.5 Bulat Pharmaceutical Recent Developments
7.18 Beacon Pharmaceuticals
7.18.1 Beacon Pharmaceuticals Comapny Information
7.18.2 Beacon Pharmaceuticals Business Overview
7.18.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.18.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.18.5 Beacon Pharmaceuticals Recent Developments
7.19 Bayer Pharmaceuticals
7.19.1 Bayer Pharmaceuticals Comapny Information
7.19.2 Bayer Pharmaceuticals Business Overview
7.19.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.19.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
7.19.5 Bayer Pharmaceuticals Recent Developments
7.20 Apotex Inc.
7.20.1 Apotex Inc. Comapny Information
7.20.2 Apotex Inc. Business Overview
7.20.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.20.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
7.20.5 Apotex Inc. Recent Developments
7.21 Actavis Generics
7.21.1 Actavis Generics Comapny Information
7.21.2 Actavis Generics Business Overview
7.21.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.21.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
7.21.5 Actavis Generics Recent Developments
8 North America
8.1 North America Gastrointestinal Stromal Tumor Drug Market Size by Type
8.1.1 North America Gastrointestinal Stromal Tumor Drug Revenue by Type (2020-2031)
8.1.2 North America Gastrointestinal Stromal Tumor Drug Sales by Type (2020-2031)
8.1.3 North America Gastrointestinal Stromal Tumor Drug Price by Type (2020-2031)
8.2 North America Gastrointestinal Stromal Tumor Drug Market Size by Application
8.2.1 North America Gastrointestinal Stromal Tumor Drug Revenue by Application (2020-2031)
8.2.2 North America Gastrointestinal Stromal Tumor Drug Sales by Application (2020-2031)
8.2.3 North America Gastrointestinal Stromal Tumor Drug Price by Application (2020-2031)
8.3 North America Gastrointestinal Stromal Tumor Drug Market Size by Country
8.3.1 North America Gastrointestinal Stromal Tumor Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Gastrointestinal Stromal Tumor Drug Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe Gastrointestinal Stromal Tumor Drug Market Size by Type
9.1.1 Europe Gastrointestinal Stromal Tumor Drug Revenue by Type (2020-2031)
9.1.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Type (2020-2031)
9.1.3 Europe Gastrointestinal Stromal Tumor Drug Price by Type (2020-2031)
9.2 Europe Gastrointestinal Stromal Tumor Drug Market Size by Application
9.2.1 Europe Gastrointestinal Stromal Tumor Drug Revenue by Application (2020-2031)
9.2.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Application (2020-2031)
9.2.3 Europe Gastrointestinal Stromal Tumor Drug Price by Application (2020-2031)
9.3 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country
9.3.1 Europe Gastrointestinal Stromal Tumor Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Gastrointestinal Stromal Tumor Drug Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China Gastrointestinal Stromal Tumor Drug Market Size by Type
10.1.1 China Gastrointestinal Stromal Tumor Drug Revenue by Type (2020-2031)
10.1.2 China Gastrointestinal Stromal Tumor Drug Sales by Type (2020-2031)
10.1.3 China Gastrointestinal Stromal Tumor Drug Price by Type (2020-2031)
10.2 China Gastrointestinal Stromal Tumor Drug Market Size by Application
10.2.1 China Gastrointestinal Stromal Tumor Drug Revenue by Application (2020-2031)
10.2.2 China Gastrointestinal Stromal Tumor Drug Sales by Application (2020-2031)
10.2.3 China Gastrointestinal Stromal Tumor Drug Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Gastrointestinal Stromal Tumor Drug Market Size by Type
11.1.1 Asia Gastrointestinal Stromal Tumor Drug Revenue by Type (2020-2031)
11.1.2 Asia Gastrointestinal Stromal Tumor Drug Sales by Type (2020-2031)
11.1.3 Asia Gastrointestinal Stromal Tumor Drug Price by Type (2020-2031)
11.2 Asia Gastrointestinal Stromal Tumor Drug Market Size by Application
11.2.1 Asia Gastrointestinal Stromal Tumor Drug Revenue by Application (2020-2031)
11.2.2 Asia Gastrointestinal Stromal Tumor Drug Sales by Application (2020-2031)
11.2.3 Asia Gastrointestinal Stromal Tumor Drug Price by Application (2020-2031)
11.3 Asia Gastrointestinal Stromal Tumor Drug Market Size by Country
11.3.1 Asia Gastrointestinal Stromal Tumor Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Gastrointestinal Stromal Tumor Drug Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Gastrointestinal Stromal Tumor Drug Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Gastrointestinal Stromal Tumor Drug Market Size by Type
12.1.1 SAMEA Gastrointestinal Stromal Tumor Drug Revenue by Type (2020-2031)
12.1.2 SAMEA Gastrointestinal Stromal Tumor Drug Sales by Type (2020-2031)
12.1.3 SAMEA Gastrointestinal Stromal Tumor Drug Price by Type (2020-2031)
12.2 SAMEA Gastrointestinal Stromal Tumor Drug Market Size by Application
12.2.1 SAMEA Gastrointestinal Stromal Tumor Drug Revenue by Application (2020-2031)
12.2.2 SAMEA Gastrointestinal Stromal Tumor Drug Sales by Application (2020-2031)
12.2.3 SAMEA Gastrointestinal Stromal Tumor Drug Price by Application (2020-2031)
12.3 SAMEA Gastrointestinal Stromal Tumor Drug Market Size by Country
12.3.1 SAMEA Gastrointestinal Stromal Tumor Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Gastrointestinal Stromal Tumor Drug Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Gastrointestinal Stromal Tumor Drug Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Gastrointestinal Stromal Tumor Drug Value Chain Analysis
13.1.1 Gastrointestinal Stromal Tumor Drug Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Gastrointestinal Stromal Tumor Drug Production Mode & Process
13.2 Gastrointestinal Stromal Tumor Drug Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Gastrointestinal Stromal Tumor Drug Distributors
13.2.3 Gastrointestinal Stromal Tumor Drug Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.